SCHEMBL680466

SCHEMBL680466

Cc1cccc(Oc2ccc(C(=O)NS(C)(=O)=O)cc2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EZH2 Q15910 1/20 0.54
HTT P42858 2/20 0.54
TDP1 Q9NUW8 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
HSD17B1 P14061 1/20 0.53
HSD17B2 P37059 1/20 0.53
MAPK1 P28482 1/20 0.50
GFER P55789 1/20 0.50
ALDH1A1 P00352 1/20 0.49
SCN9A Q15858 4/20 0.48
SCN2B O60939 2/20 0.48
SCN1A P35498 2/20 0.48
SCN1B Q07699 2/20 0.48
MCL1 Q07820 3/20 0.48
BCL2L1 Q07817 2/20 0.48
MMP13 P45452 2/20 0.48
POLB P06746 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
NPC1 O15118 1/20 0.47
TP53 P04637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL680496 0.87 MMP13 (0.51) HTTALDH1A1SCN9AMCL1BCL2L1
SCHEMBL680286 0.86 PGR (0.60) ALDH1A1SCN9ASCN2BSCN1ASCN1B
SCHEMBL17171690 0.85 HSD17B1 (0.56) EZH2HTTTDP1L3MBTL1HSD17B1
SCHEMBL680561 0.85 MMP13 (0.65) HTTGFERALDH1A1SCN9AMCL1
SCHEMBL678903 0.85 BCL2L1 (0.52) L3MBTL1ALDH1A1SCN9ASCN2BSCN1A
SCHEMBL678831 0.85 BCL2L1 (0.52) HTTALDH1A1SCN9ASCN2BSCN1A
SCHEMBL679785 0.84 MCL1 (0.62) TDP1SCN9AMCL1BCL2L1HDAC8
SCHEMBL679703 0.83 SCN9A (0.49) HTTTDP1L3MBTL1GFERSCN9A
SCHEMBL679782 0.83 SCN9A (0.50) HTTSCN9AMCL1BCL2L1SMN1; SMN2
SCHEMBL679983 0.83 ACACB (0.50) L3MBTL1MAPK1MCL1BCL2L1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2593427-B1 SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN PFIZER LTD (GB) 2014-12-24 EP disclosed
US-20120010207-A1 Chemical Compounds PFIZER LIMITED (GB) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010207-A1 Chemical Compounds SCN1A, SCN1B, SCN7A EZH2 4401/4885HTT 1281/4885TDP1 2009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.